Men with prostate cancer want to know the future: Will my cancer get worse? Do I need surgery? Genomic testing can help us make educated recommendations, but it’s far from perfect. Claus Roehrborn, M.D., explains why genomic testing isn’t a “crystal ball” for predicting prostate cancer risk.
Dr. Claus Roehrborn and colleagues in Urology and Radiology are using a new, targeted biopsy method for prostate cancer that’s more effective than standard biopsies – and they’ve just reached a significant milestone.